• CEO interview: Growth Strategy of Shionogi

What's New

  • Show All
2019/11/01
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
2019/10/31
1st Half of Fiscal 2019Financial Results
2019/10/30
Financial Results for the Second Quarter of FY2019
2019/10/30
Shionogi Announces Commencement of Tender Offer for Certificates of Shares, Etc. in UMN Pharma Inc. (Securities Code: 8840)
2019/10/28
Launch of “BNP Control Shionogi”, a Common Reference Standard Material for BNP Test
2019/10/28
Shionogi Provides Update on the Japanese Association for Infectious Diseases Statement and the Revised Guidelines of the Japanese Pediatric Society for the Treatment of Influenza
2019/10/18
FDA Approves XOFLUZA™ (Baloxavir Marboxil) for the Treatment of Acute Uncomplicated Influenza for People at High Risk of Developing Influenza-Related Complications
2019/10/18
Shionogi, Janssen, and Alzheimer’s Drug Discovery Foundation Announced a “Clinical Sample Access Agreement” at WDC 2019 Summit
2019/10/17
U.S. FDA Advisory Committee Recommends Approval of Cefiderocol for Treatment of Complicated Urinary Tract Infections
2019/10/16
Shionogi Filed for the Supplemental New Drug Application of XOFLUZA® in Japan for the Post-Exposure Prophylaxis of Influenza Virus Infection
2019/10/11
Shionogi Received “2019 Award for Excellence in Corporate Disclosure” for Three Consecutive Year from the Securities Analysts Association of Japan (SAAJ)
2019/10/11
Shionogi enters into a new license agreement and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.
2019/10/04
M3 and Shionogi Joint Venture for Disease Solution - Establishment of Stream-I, Inc. -